Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Buy
52
TGTX Quote, Financials, Valuation and Earnings
Last price:
$30.85
Seasonality move
:
39.8%
Day range:
$29.90 - $32.10
52-week range:
$12.84 - $36.84
Dividend yield:
0%
P/E ratio:
39.15x
P/S ratio:
17.69x
P/B ratio:
24.38x
Volume:
2.1M
Avg. volume:
2.2M
1-year change:
76.23%
Market cap:
$4.7B
Revenue:
$233.7M
EPS (TTM):
-$0.11
Analysts' Opinion
-
Consensus RatingTG Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $38.67, TG Therapeutics has an estimated upside of 35.38% from its current price of $30.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $30.10.
Fair Value
-
According to the consensus of 7 analysts, TG Therapeutics has 35.38% upside to fair value with a price target of $38.67 per share.
TGTX vs. S&P 500
-
Over the past 5 trading days, TG Therapeutics has underperformed the S&P 500 by -4.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TG Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TG Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter TG Therapeutics reported revenues of $83.9M.
Earnings Growth
-
TG Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter TG Therapeutics reported earnings per share of $0.02.
Enterprise value:
4.6B
EV / Invested capital:
--
Price / LTM sales:
17.69x
EV / EBIT:
813.16x
EV / Revenue:
17.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-163.24x
Price / Operating cash flow:
53.48x
Enterprise value / EBITDA:
770.94x
Gross Profit (TTM):
$233.9M
Return On Assets:
-3.55%
Net Income Margin (TTM):
-5.43%
Return On Equity:
-8.4%
Return On Invested Capital:
-4.78%
Operating Margin:
14.82%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5M | $189.8M | $264.8M | $165.8M | $83.9M | |
| Gross Profit | $4.6M | $183.5M | $233.9M | $162.3M | $74.5M | |
| Operating Income | -$233.7M | -$18.9M | -$505K | $114.8M | $12.4M | |
| EBITDA | -$229.7M | -$12.4M | $6M | $117.8M | $15.2M | |
| Diluted EPS | -$1.77 | -$0.28 | -$0.11 | $0.73 | $0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $260.3M | $371.8M | $182.9M | $319.1M | $574.1M | |
| Total Assets | $273.9M | $409.7M | $217.9M | $331.1M | $586M | |
| Current Liabilities | $77.7M | $87.7M | $36.4M | $57.7M | $125.1M | |
| Total Liabilities | $103.2M | $98.2M | $117.4M | $166.3M | $393.9M | |
| Total Equity | $170.7M | $311.5M | $100.5M | $164.8M | $192.2M | |
| Total Debt | $29.7M | $16M | $70M | $98.9M | $244.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$239.2M | -$42.1M | -$28.1M | $83.7M | -$12.2M | |
| Cash From Investing | -$33M | $10.4M | -$61.6M | -$30.2M | -$9.3M | |
| Cash From Financing | $55.6M | $72.8M | $134.6M | $421K | $134.5M | |
| Free Cash Flow | -$239.3M | -$42.1M | -$28.1M | $83.7M | -$12.2M | |
TGTX
Sector
Market Cap
$4.7B
$47.7M
Price % of 52-Week High
81.71%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
76.23%
-33.33%
Beta (5-Year)
2.245
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$31.90
200-day SMA
Buy
Level
$21.85
Bollinger Bands (100)
Buy
Level
22.09 - 31.33
Chaikin Money Flow
Buy
Level
35.6M
20-day SMA
Sell
Level
$32.40
Relative Strength Index (RSI14)
Sell
Level
43.41
ADX Line
Sell
Level
25.8
Williams %R
Buy
Level
-96.1014
50-day SMA
Sell
Level
$30.38
MACD (12, 26)
Buy
Level
0.15
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
336M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.6731)
Buy
CA Score
(Annual)
Level (-0.0447)
Sell
Beneish M-Score
(Annual)
Level (71.2541)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-8.8664)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Stock Forecast FAQ
In the current month, TGTX has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TGTX average analyst price target in the past 3 months is $38.67.
-
Where Will TG Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that TG Therapeutics share price will rise to $38.67 per share over the next 12 months.
-
What Do Analysts Say About TG Therapeutics?
Analysts are divided on their view about TG Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TG Therapeutics is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is TG Therapeutics's Price Target?
The price target for TG Therapeutics over the next 1-year time period is forecast to be $38.67 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is TGTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TG Therapeutics is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TGTX?
You can purchase shares of TG Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TG Therapeutics shares.
-
What Is The TG Therapeutics Share Price Today?
TG Therapeutics was last trading at $30.85 per share. This represents the most recent stock quote for TG Therapeutics. Yesterday, TG Therapeutics closed at $30.10 per share.
-
How To Buy TG Therapeutics Stock Online?
In order to purchase TG Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Adobe Stock Dropping?
Why is Adobe stock dropping? A combination of underwhelming fiscal…
Why Is 3M Stock Going Up?
After a decade-long slump in new product introductions, the leading…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
77
FTAI alert for Jan 2
FTAI Aviation [FTAI] is up 0.96% over the past day.
Buy
56
QMCO alert for Jan 2
Quantum [QMCO] is down 0.22% over the past day.
Buy
60
ARQQ alert for Jan 2
Arqit Quantum [ARQQ] is down 3.4% over the past day.
